[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630728":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":46,"responsibleParty":240,"collaborators":31,"id":242,"slug":31,"hasResults":243,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":243,"sex":249,"minAge":250,"maxAge":31,"enrollmentInfo":251,"targetDuration":31,"studyType":254,"phases":255,"briefSummary":257,"conditions":258,"keywords":267,"overallStatus":49,"whyStopped":31,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: daraxonrasib","EXPERIMENTAL","study drug",[13],"Drug: daraxonrasib",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm B: daraxonrasib + gemcitabine and nab-paclitaxel","study drug in combination with chemotherapy",[13,18,19],"Drug: gemcitabine","Drug: nab-paclitaxel",{"label":21,"type":22,"description":23,"interventionNames":24},"Arm C: gemcitabine and nab-paclitaxel","ACTIVE_COMPARATOR","SOC chemotherapy",[18,19],[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","daraxonrasib","oral tablets",[9,15],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"gemcitabine","intravenous (IV) infusion",[15,21],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"nab-paclitaxel","IV infusion",[15,21],[41],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[47,65,80,95,110,124,139,153,168,183,198,213,227],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"H Lee Moffitt Cancer Center and Research Institute","RECRUITING","Tampa","Florida","33612","United States",{"type":55,"coordinates":56},"Point",[57,58],-82.45843,27.94752,{"lat":58,"lon":57},[61],{"name":62,"role":43,"phone":63,"phoneExt":31,"email":64},"Cheyenne Schneider","813-745-3691","cheyenne.schneider@moffitt.org",{"facility":66,"status":49,"city":67,"state":68,"zip":69,"country":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center","Baltimore","Maryland","21287",{"type":55,"coordinates":71},[72,73],-76.61219,39.29038,{"lat":73,"lon":72},[76],{"name":77,"role":43,"phone":78,"phoneExt":31,"email":79},"Colleen Apostol","410-614-3644","giclinicaltrials@jhmi.edu",{"facility":81,"status":49,"city":82,"state":83,"zip":84,"country":53,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":55,"coordinates":86},[87,88],-71.05977,42.35843,{"lat":88,"lon":87},[91],{"name":92,"role":43,"phone":93,"phoneExt":31,"email":94},"Brian Wolpin","857-215-2351","DanielleA_Lindquist@DFCI.HARVARD.EDU",{"facility":96,"status":49,"city":97,"state":98,"zip":99,"country":53,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Comprehensive Cancer Centers of Nevada","Henderson","Nevada","89052",{"type":55,"coordinates":101},[102,103],-114.98194,36.0397,{"lat":103,"lon":102},[106],{"name":107,"role":43,"phone":108,"phoneExt":31,"email":109},"Ann Lovelace","702-609-9460","ann.lovelace@usoncology.com",{"facility":111,"status":49,"city":112,"state":112,"zip":113,"country":53,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":55,"coordinates":115},[116,117],-74.00597,40.71427,{"lat":117,"lon":116},[120],{"name":121,"role":43,"phone":122,"phoneExt":31,"email":123},"Wungki Park","646-888-4543","parkw1@mskcc.org",{"facility":125,"status":49,"city":126,"state":127,"zip":128,"country":53,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"University of Cincinnati Cancer Center","Cincinnati","Ohio","45219",{"type":55,"coordinates":130},[131,132],-84.51439,39.12711,{"lat":132,"lon":131},[135],{"name":136,"role":43,"phone":137,"phoneExt":31,"email":138},"Alexis Brenner","513-584-5725","brenneas@ucmail.uc.edu",{"facility":140,"status":49,"city":141,"state":127,"zip":142,"country":53,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Taylor Cancer Research Center","Maumee","43537",{"type":55,"coordinates":144},[145,146],-83.65382,41.56283,{"lat":146,"lon":145},[149],{"name":150,"role":43,"phone":151,"phoneExt":31,"email":152},"Stephanie Ambrose","567-402-4502","sambrose@toledoclinic.com",{"facility":154,"status":49,"city":155,"state":156,"zip":157,"country":53,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":55,"coordinates":159},[160,161],-86.78444,36.16589,{"lat":161,"lon":160},[164],{"name":165,"role":43,"phone":166,"phoneExt":31,"email":167},"Karlie Williams","615-329-7274","karlie.williams@scri.com",{"facility":169,"status":49,"city":170,"state":171,"zip":172,"country":53,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"SCRI - Texas Oncology Dallas","Dallas","Texas","95246",{"type":55,"coordinates":174},[175,176],-96.80667,32.78306,{"lat":176,"lon":175},[179],{"name":180,"role":43,"phone":181,"phoneExt":31,"email":182},"Christine Terraciano","214-370-1000","christine.terraciano@usoncology.com",{"facility":184,"status":49,"city":185,"state":186,"zip":187,"country":53,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Virginia Cancer Specialists","Fairfax","Virginia","22031",{"type":55,"coordinates":189},[190,191],-77.30637,38.84622,{"lat":191,"lon":190},[194],{"name":195,"role":43,"phone":196,"phoneExt":31,"email":197},"Carrie Friedman","571-350-8400","carrie.friedman@usoncology.com",{"facility":199,"status":49,"city":200,"state":201,"zip":202,"country":53,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Virginia Mason Medical Center","Seattle","Washington","98101",{"type":55,"coordinates":204},[205,206],-122.33207,47.60621,{"lat":206,"lon":205},[209],{"name":210,"role":43,"phone":211,"phoneExt":31,"email":212},"Das Rishika","206-287-6273","rishika.das@commonspirit.org",{"facility":214,"status":49,"city":215,"state":31,"zip":216,"country":217,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Wakayama Medical University Hospital","Wakayama","641-8510","Japan",{"type":55,"coordinates":219},[220,221],135.16667,34.23333,{"lat":221,"lon":220},[224],{"name":225,"role":43,"phone":226,"phoneExt":31,"email":31},"Reiko Ashida","+81-73-447-2300",{"facility":228,"status":49,"city":229,"state":31,"zip":230,"country":217,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Yamaguchi University Hospital","Yamaguchi","755-8505",{"type":55,"coordinates":232},[233,234],131.46667,34.18333,{"lat":234,"lon":233},[237],{"name":238,"role":43,"phone":239,"phoneExt":31,"email":31},"Tatsuya Ioka","+81-836-22-2111",{"type":241,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100630728",false,"NCT07491445","Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma","RASolute 303","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed pancreatic adenocarcinoma.\n* Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.\n* Documented RAS mutation status, either mutant or wild-type.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.\n* Active or known history of untreated central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.","ALL","18 Years",{"count":252,"type":253},900,"ESTIMATED","INTERVENTIONAL",[256],"PHASE3","The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.",[259,260,261,262,263,264,265,266],"Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma",[259,261,268,269,270,271,272,273,274,260,264,266,265],"Pancreatic Ductal Adenocarcinoma","RAS","KRAS","NRAS","HRAS","RAS Wild-Type","RAS Mutation","2026-06-24",{"date":277,"type":278},"2026-06-25","ACTUAL",{"date":280,"type":278},"2026-03-09",{"date":282,"type":253},"2029-03",{"name":5,"class":6},13]